Relugolix and radiation for high risk prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a medication called relugolix (which lowers testosterone) combined with radiation therapy for men with aggressive prostate cancer. The goal is to see if this combination can better control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with high-risk or very high-risk prostate cancer
- You are 18 years or older
- You have not had your prostate removed (no prior prostatectomy)
- You are not currently on hormone therapy (or your testosterone has recovered)
- You have not had pelvic radiation in the past
- You are generally healthy and able to be up and about
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two hormone therapy combinations for men with prostate cancer that hasn't spread. The goal is to see if a newer oral medication (Relugolix) plus abiraterone works better than the standard injectable therapy (Lupron) plus abiraterone, while also checking heart safety.
This trial tests if giving a short-term hormone pill (relugolix) before a special PSMA PET/CT scan makes the scan clearer for men with high-risk prostate cancer. It may help doctors better see where the cancer is.
This trial compares two hormone therapies, relugolix and leuprolide, to see which one is better for your heart health in men with prostate cancer. It's for men with a specific type of prostate cancer that is not yet advanced.
This study tests whether a combination of short-term hormone therapy (relugolix) and focused radiation (SBRT) can treat a certain type of prostate cancer that is considered favorable but has a higher genetic risk. It aims to find a less intense treatment that still works well.
This trial tests whether combining two hormone therapy drugs, relugolix and enzalutamide, with radiation therapy can help treat very high-risk prostate cancer. The goal is to see if this combination is safe and effective for men whose cancer has a high chance of coming back.
This trial tests a combination of two oral drugs, relugolix and enzalutamide, in men with high-risk prostate cancer that hasn't spread to distant parts of the body. The goal is to see if this treatment can help control the cancer before or alongside local therapies like surgery or radiation.
Hear when a new Stage IIC Prostate Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.